Methods for evaluating the stage of ovarian cancer or the survival rate of an ovarian cancer patientJohji InazawaIssei ImotoRyoko_Kikuchi
- 《Cancer》 被引量: 54发表: 2010年 Cisplatin and Etoposide Versus Carboplatin and Paclitaxel With Concurrent Radiation for Stage III Non-Small-Cell Lung Cancer: Is There an Impact on Radiati... BACKGROUNDThe authors compared the toxicity, response rate, and progression free survival of four ...
aOvarian cancer has one of the highest mortality rates of all gynecologic malignant tumors. More than 70% of patients are late-stage at diagnosis [1], and the 5-year survival rate is approximately 19~40% [2-3]. Locoregional recurrence and distant metastases are ominous events in patients wi...
In contrast, for the few patients (~15%) diagnosed with localized disease, the 5-year survival rate rises to about 25% and when PDAC is detected at Stage I, survival rates can be as high as 80%3. Likewise, ovarian cancer typically has few symptoms and is often undetected until it is...
In advanced gastric cancer patients treated mainly with 5-FU or cisplatin-based chemotherapy, lower expression of EGFR mRNA than the cutoff value was a strong predictor of poor survival by multivariate analysis (Matsubara et al, 2008a). Interestingly, the authors also showed that high DPD and ...
Epithelial ovarian cancer IDS: Interval cytoreduction surgery NAC: Neoadjuvant chemotherapy OS: Overall survival PDS: Primary debulking surgery PFS: Progression free survival References Hannibal CG, et al. Survival of ovarian cancer patients in Denmark: excess mortality risk analysis of five-year...
(Kisqali) to endocrine therapy continued to significantly improve OS and delay subsequent chemotherapy compared with placebo, irrespective of endocrine partner, in pre- and peri-menopausal patients with hormone receptor–positive, HER2-negative breast cancer in combination with suppression of ovarian ...
To establish your receptor status, a sample of cancer cells would need to be obtained bybiopsyorsurgery. Bonefos and Zometa should only be used in women who were postmenopausal at the time of their diagnosis or are premenopausal but have receivedovarian suppression therapyto stop their ovaries fr...
Ovarian cancer is associated with the highest mortality rate among gynecologic malignancies. The ovaries have a relatively inaccessible location and ovarian cancer patients very often lack symptoms in early stages. Around 70% of the cases are diagnosed at advanced stages of the disease, with either ...
S-1 plus cisplatin may provide some benefit as first-line chemotherapy for patients with FIGO stage IVB, recurrent, or persistent cervical cancer in terms of PFS and ORR compared with cisplatin alone, although contribution to survival is unclear. Given that the standard therapy for this population...